clinical trials with Olaparib as a mono therapy in hormone sensitive prostate cancer?

[Brysonal]

does anyone know if this is happening anywhere at all

Regards

[Benkaymel]

I don't know of one, but I tested (and failed) for the AMPLITUDE trial which is Olaparib plus SOC. I would be uneasy having Olaparib on it's own TBH.

[Brysonal in reply to Benkaymel]

in research mode only - thanks for the reply

[pjoshea13]

I was interested to read that:

"In December 2014, the US Food and Drug Administration (FDA) ... approved olaparib as monotherapy ... in germline BRCA mutated (gBRCAm) advanced ovarian cancer that has received three or more prior lines of chemotherapy." [1]

Also in 2014 there was a paper [2] that actually mentioned monotherapy in PCa patients:

"This multicenter phase II study enrolled individuals with a germline BRCA1/2 mutation and recurrent cancer. Eligibility included ... prostate cancer with progression on hormonal and one systemic therapy. Olaparib was administered at 400 mg twice per day. The primary efficacy end point was tumor response rate."

"Results: A total of 298 patients received treatment and were evaluable. The tumor response rate was ... 50.0% (four of eight ...) ... with ... prostate cancers ..."

"... Stable disease ≥ 8 weeks was observed in ... 25% ... with ... prostate cancer ..."

There are 20 PubMed hits for "Olaparib monotherapy"[title], albeit not PCa papers. [3]

-Patrick

[1] en.wikipedia.org/wiki/Olaparib

[2] pubmed.ncbi.nlm.nih.gov/253...

[3] pubmed.ncbi.nlm.nih.gov/?te...

[Brysonal]

wow . Thank you for that

[Brysonal]

thank you

[Benkaymel]

Yes, that looks like AMPLITUDE.

[Benkaymel]

Oh ok but very similar (same drugs).

[Benkaymel]

Yes you're right. My bad ☹️

[Benkaymel]

👍